GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » PB Ratio
中文

Salarius Pharmaceuticals (Salarius Pharmaceuticals) PB Ratio

: 0.38 (As of Today)
View and export this data going back to 2015. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), Salarius Pharmaceuticals's share price is $0.5096. Salarius Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $1.34. Hence, Salarius Pharmaceuticals's PB Ratio of today is 0.38.

The historical rank and industry rank for Salarius Pharmaceuticals's PB Ratio or its related term are showing as below:

SLRX' s PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.86   Max: 4.65
Current: 0.38

During the past 10 years, Salarius Pharmaceuticals's highest PB Ratio was 4.65. The lowest was 0.07. And the median was 0.86.

SLRX's PB Ratio is ranked better than
94.89% of 1310 companies
in the Biotechnology industry
Industry Median: 2.38 vs SLRX: 0.38

During the past 12 months, Salarius Pharmaceuticals's average Book Value Per Share Growth Rate was -70.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -61.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -63.30% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Salarius Pharmaceuticals was -55.60% per year. The lowest was -71.70% per year. And the median was -60.45% per year.

Back to Basics: PB Ratio


Salarius Pharmaceuticals PB Ratio Historical Data

The historical data trend for Salarius Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.61 0.98 0.58 0.33 0.48

Salarius Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.85 0.59 0.43 0.48

Competitive Comparison

For the Biotechnology subindustry, Salarius Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's PB Ratio falls into.



Salarius Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Salarius Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.5096/1.342
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Salarius Pharmaceuticals  (NAS:SLRX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Salarius Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Executives
Tess Burleson director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber director C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar director C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum officer: Exec VP Finance, Interim CFO 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur director, officer: Chief Executive Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan officer: Chief Financial Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr. director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang officer: Controller 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers director 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc. 10 percent owner 75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal 10 percent owner C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p. 10 percent owner 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Headlines

From GuruFocus